Business & Financial News, Breaking US & International News | Reuters
Edition:
United States

Biotechnology & Medical Research

Page 2

QIAGEN offer for Exiqon completed

Thursday, 23 Jun 2016 03:43am EDT

Exiqon A/S : Announcement of the final result of the offer and completion thereof .QIAGEN N.V. intends to apply for delisting of shares of Exiqon and initiate squeeze-out of remaining minority shareholders.

Bioxyne signs agreement with Datapharm to undertake a clinical trial

Wednesday, 22 Jun 2016 11:08pm EDT

Bioxyne Ltd : Signed an agreement with datapharm Australia to undertake a clinical trial . Says agreement to undertake a clinical trial to support its Australian launch and marketing of progastrim® and protract .

Eleven Biotherapeutics to cut a portion of co's workforce

Wednesday, 22 Jun 2016 04:28pm EDT

Eleven Biotherapeutics Inc : Eleven Biotherapeutics Inc says on June 16 board approved a strategic restructuring to eliminate a portion of co's workforce . Board approved a strategic restructuring of the company to eliminate a portion of the company’s workforce . Will eliminate 14 positions across organization, representing approximately 70 percent of company's workforce . The company currently expects to record the restructuring charges during the second and third quarters of 2016 . Currently anticipates incurring total restructuring costs of approximately $0.9 million .Currently expects to record restructuring charges during second and third quarters of 2016.

Eiger Biopharmaceuticals CFO Welch buys 2500 shares of common stock at avg price of $19.79/shr - SEC filing

Wednesday, 22 Jun 2016 02:49pm EDT

Eiger Biopharmaceuticals Inc :CFO James Welch reports purchase of 2500 shares of company's common stock at average price of $19.79 per share - SEC filing.

Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody

Wednesday, 22 Jun 2016 08:50am EDT

Agenus Inc : Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months .Agenus announces commencement of phase 1/2 clinical trial of anti-GITR checkpoint antibody INCAGN1876 in patients with solid tumors.

Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody

Wednesday, 22 Jun 2016 08:50am EDT

Agenus Inc : Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months .Agenus announces commencement of phase 1/2 clinical trial of anti-GITR checkpoint antibody INCAGN1876 in patients with solid tumors.

Redhill Biopharma says drug for Crohn's disease shows potential efficacy in trial

Wednesday, 22 Jun 2016 08:00am EDT

Redhill Biopharma Announces Publication Demonstrating Potential Efficacy Of Rhb : 104 for crohn's disease associated with map infection . Interim data and safety monitoring board (dsmb) analysis expected in second half of 2016 for rhb-104 .Final results from phase iia proof-of-concept study with rhb-104 in multiple sclerosis are also expected in second half of 2016.

Karyopharm says initiates phase 1 clinical trial with KPT-9274

Wednesday, 22 Jun 2016 07:30am EDT

Karyopharm : Says first-In-Human, multi-center, open-label, dose-escalation trial is expected to enroll up to 175 patients .Says initiates Phase 1 Clinical Trial With Kpt-9274.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Edison Investment Research
$10.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.